Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.

Phase 2 Terminated NCT06447506

Summary

The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have completed phase 2b parent GSK atopic dermatitis (AtD) study (NCT05999799).

Number of Participants With Treatment Emergent Adverse Events (TEAEs)

Up to Week 59 · Participants

Number of Participants With TEAEs Leading to Permanent Discontinuation

Up to Week 59 · Participants

Number of Participants With Serious Adverse Events (SAEs)

Up to Week 59 · Participants

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moder — LEO Pharma
• A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis — Eli Lilly and Company
• Aquacel Hypersensitivity Dressing in TJAs — Rush University Medical Center
• A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Par — Amgen
• A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) — Amgen
• A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic D — Amgen

All trials